OC
AQST icon

Oppenheimer & Co’s Aquestive Therapeutics AQST Stock Holding History

Oppenheimer & Co’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
51,052
+13,167
+35% +$55.4K ﹤0.01% 1637
2026
Q1 		$157K Buy
+37,885
New +$154K ﹤0.01% 1604
2025
Q4 		– Sell
-33,532
Closed -$187K – 1561
2025
Q3 		$187K Buy
+33,532
New +$145K ﹤0.01% 1556

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Oppenheimer & Co's AQST Position: Q2 2026 in Review

Oppenheimer & Co increased its Aquestive Therapeutics (AQST) stake by 35% in Q2 2026, buying an estimated $55.4K and bringing the position to 51,052 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

Oppenheimer & Co first reported a position in AQST in Q3 2025 and has held it in 3 quarters since. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Oppenheimer & Co held 51,052 shares of Aquestive Therapeutics worth $212K as of Q2 2026.
  • Oppenheimer & Co bought 13,167 Aquestive Therapeutics shares in Q2 2026, an estimated $55.4K.
  • Aquestive Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1637 holding.
  • Oppenheimer & Co first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.